Agenus Inc. (NASDAQ:AGEN) traded down 6.1% during mid-day trading on Tuesday . The company traded as low as $3.35 and last traded at $3.37. 1,907,088 shares changed hands during mid-day trading, an increase of 61% from the average session volume of 1,186,853 shares. The stock had previously closed at $3.59.

A number of equities research analysts have issued reports on the company. Zacks Investment Research raised Agenus from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Wednesday, October 25th. BidaskClub lowered Agenus from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Finally, ValuEngine raised Agenus from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Agenus has a consensus rating of “Hold” and a consensus target price of $5.81.

The company has a debt-to-equity ratio of -2.39, a quick ratio of 1.55 and a current ratio of 1.55.

Agenus (NASDAQ:AGEN) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). The business had revenue of $3.40 million for the quarter, compared to analyst estimates of $5.91 million. Agenus’s revenue was down 24.4% on a year-over-year basis. equities research analysts forecast that Agenus Inc. will post -1.19 EPS for the current fiscal year.

In other Agenus news, CEO Garo H. Armen bought 100,000 shares of the business’s stock in a transaction dated Monday, October 30th. The shares were acquired at an average price of $3.55 per share, with a total value of $355,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 7.60% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. Cubist Systematic Strategies LLC acquired a new position in Agenus during the third quarter worth approximately $134,000. OxFORD Asset Management LLP acquired a new position in Agenus during the second quarter worth approximately $141,000. Voya Investment Management LLC increased its position in Agenus by 18.5% during the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock worth $160,000 after buying an additional 6,381 shares during the period. State of Wisconsin Investment Board acquired a new position in Agenus during the second quarter worth approximately $207,000. Finally, Metropolitan Life Insurance Co. NY increased its position in Agenus by 12.2% during the first quarter. Metropolitan Life Insurance Co. NY now owns 55,920 shares of the biotechnology company’s stock worth $211,000 after buying an additional 6,101 shares during the period. 37.90% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Agenus (AGEN) Stock Price Down 6.1%” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.watchlistnews.com/agenus-agen-stock-price-down-6-1/1763472.html.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with Analyst Ratings Network's FREE daily email newsletter.